Psoriasis patients with moderate to severe disease often present with depression and insomnia. Treatment targeting both psoriasis and psychological comorbidities is needed to improve the quality of life of these patients.In this nationwide cohort study, a total of 980 patients with psoriatic arthritis or psoriasis who had received nonbiological disease-modifying antirheumatic drugs and biologics therapy between 2009 and 2012 were identified. The prevalence rates of patients taking medications for depression and insomnia were compared before and after biologics therapy. Logistic regression method was used to investigate the risk factors for depression and insomnia. Further stratified analyses were performed to examine the prevalence of use of medications for depression and insomnia among different patient subgroups.The prevalence of patients taking regular antidepressants before starting biologics therapy was about 20%. There was a more than 40% reduction in this prevalence after biologics therapy for 2 years. Age higher than 45 years, female sex, presence of comorbidities, and psoriatic arthritis were independently associated with depression and insomnia. Further stratified analyses revealed a more rapid and significant reduction in depression/insomnia in those undergoing continuous biologics therapy, younger than 45 years, without psoriatic arthritis and not taking concomitant methotrexate, when compared with their counterparts.The results suggest that biologics therapy may be associated with reduced rates of depression and insomnia, and a reduced rate of regular antidepressants use in psoriasis patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900733 | PMC |
| http://dx.doi.org/10.1097/MD.0000000000003816 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Towards an ontology of mental health: Protocol for developing an ontology to structure and integrate evidence regarding anxiety, depression and psychosis.
Wellcome Open Res
November 2024
Centre for Behaviour Change, University College London, London, England, UK.
Background: Research about anxiety, depression and psychosis and their treatments is often reported using inconsistent language, and different aspects of the overall research may be conducted in separate silos. This leads to challenges in evidence synthesis and slows down the development of more effective interventions to prevent and treat these conditions. To address these challenges, the Global Alliance for Living Evidence on aNxiety, depressiOn and pSychosis (GALENOS) Project is conducting a series of living systematic reviews about anxiety, depression and psychosis.
View Article and Find Full Text PDFA multi-site feasibility study of a stepped-care telehealth intervention for depression and anxiety in post-treatment cancer survivors at community cancer clinics (WF-30917CD).
J Cancer Surviv
January 2025
Department of Biostatistical Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Purpose: This feasibility study estimated accrual, retention, adherence, and summarized preliminary efficacy data from a stepped-care telehealth intervention for cancer survivors with moderate or severe levels of anxiety and/or depressive symptoms.
Methods: Participants were randomized to intervention or enhanced usual care (stratified by symptom severity). In the intervention group, those with moderate symptoms received a cognitive-behavioral therapy (CBT) workbook/6 bi-weekly check-in calls (low intensity) and severe symptoms received the workbook/12 weekly therapy sessions (high intensity).
Background: Narcolepsy is a chronic disorder that requires lifelong management; however, few studies have evaluated disease burden of narcolepsy. We estimated the healthcare burden of narcolepsy in Japan using data from the Japan Medical Data Center health insurance claims database.
Methods: This was a retrospective analysis of clinical burden, healthcare resource utilization, and costs among incident narcolepsy cases and matched controls identified between January 1, 2014 and December 31, 2019.
Polysomnographic findings and psychiatric symptoms in patients with comorbid insomnia and sleep apnea: a retrospective study focusing on sex differences.
Sleep Breath
January 2025
Department of Psychiatry, Chungnam National University Hospital, 282 Munhwa-ro, Jung-gu, Daejeon, 35015, South Korea.
Purpose: Comorbid insomnia and obstructive sleep apnea (COMISA) present significant clinical challenges, given their overlapping symptoms and detrimental effects on health. Only a few studies have explored sex differences in patients with obstructive sleep apnea (OSA) and COMISA. This retrospective study investigated sex differences in psychiatric symptoms and polysomnographic findings between patients with COMISA and those with OSA alone.
View Article and Find Full Text PDFChange in sleep, gastrointestinal symptoms, and mood states at high altitude (4500m) for 6 months.
Sleep Breath
January 2025
Department of Neurology, 940th Hospital of Chinese People's Liberation Army Joint Logistic Support Force, Lanzhou, 730050, China.
Purpose: This study aimed to investigate the alterations in sleep quality and sleep patterns among military personnel at altitudes ranging from 1500 to 4500 m, as well as the associated factors influencing their sleep.
Methods: This study employed a longitudinal prospective survey conducted over a period of six months, from November 2023 to June 2024. A total of 90 soldiers were recruited for participation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!